Neil H Segal1, Purvi Gada2, Neil Senzer3, Michele A Gargano4, Myra L Patchen4, Leonard B Saltz5. 1. Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: segaln@mskcc.org. 2. University of Minnesota, Minneapolis, MN. 3. Mary Crowley Cancer Research Center, Dallas, TX. 4. Biothera, Eagan, MN. 5. Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
BACKGROUND: Imprime PGG (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose) is an innate immune cell modulator that primes neutrophils and monocytes/macrophages to exert antitumor activity against complement opsonized tumor cells. In patients with KRAS-mutant colorectal cancer (CRC), cetuximab alone is ineffective; however, it can bind to tumor cells and induce opsonization for recognition by Imprime PGG-bound innate immune cells. The primary objective of this study was to determine the antitumor activity of Imprime PGG in combination with cetuximab in patients with KRAS-mutant metastatic CRC. PATIENTS AND METHODS: The study had a 2-stage Simon optimal design with 80% power to detect a target objective response rate (ORR) of ≥10% at a 10% significance level. Patients received weekly Imprime PGG (4 mg/kg) and cetuximab (loading dose, 400 mg/m(2), then 250 mg/m(2)) intravenously. The primary end point was ORR; secondary end points included duration of response (DOR), time to progression (TTP), overall survival (OS), disease control rate, progression-free survival, and safety. Stage 1 of the study was to enroll 17 evaluable patients. RESULTS: One partial response (5.6%) was observed among 18 patients enrolled into stage 1. Median DOR was 4.2 months, TTP 2.7 months, and OS 6.6 months. Overall, observed toxicity was as expected from cetuximab alone. The most common (≥20%) adverse events related to Imprime PGG were fatigue (7 patients; 38.9%), infusion reaction (4 patients; 22.2%), and headache (4 patients; 22.2%). There was no Grade 4 toxicity nor treatment-related deaths. CONCLUSION: Imprime PGG in combination with cetuximab treatment in patients with KRAS-mutant CRC showed compelling, albeit modest, clinical activity. This study provides proof of principle that Imprime PGG, in combination with complement-activating antibodies, is associated with clinical activity.
BACKGROUND: Imprime PGG (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose) is an innate immune cell modulator that primes neutrophils and monocytes/macrophages to exert antitumor activity against complement opsonized tumor cells. In patients with KRAS-mutant colorectal cancer (CRC), cetuximab alone is ineffective; however, it can bind to tumor cells and induce opsonization for recognition by Imprime PGG-bound innate immune cells. The primary objective of this study was to determine the antitumor activity of Imprime PGG in combination with cetuximab in patients with KRAS-mutant metastatic CRC. PATIENTS AND METHODS: The study had a 2-stage Simon optimal design with 80% power to detect a target objective response rate (ORR) of ≥10% at a 10% significance level. Patients received weekly Imprime PGG (4 mg/kg) and cetuximab (loading dose, 400 mg/m(2), then 250 mg/m(2)) intravenously. The primary end point was ORR; secondary end points included duration of response (DOR), time to progression (TTP), overall survival (OS), disease control rate, progression-free survival, and safety. Stage 1 of the study was to enroll 17 evaluable patients. RESULTS: One partial response (5.6%) was observed among 18 patients enrolled into stage 1. Median DOR was 4.2 months, TTP 2.7 months, and OS 6.6 months. Overall, observed toxicity was as expected from cetuximab alone. The most common (≥20%) adverse events related to Imprime PGG were fatigue (7 patients; 38.9%), infusion reaction (4 patients; 22.2%), and headache (4 patients; 22.2%). There was no Grade 4 toxicity nor treatment-related deaths. CONCLUSION: Imprime PGG in combination with cetuximab treatment in patients with KRAS-mutant CRC showed compelling, albeit modest, clinical activity. This study provides proof of principle that Imprime PGG, in combination with complement-activating antibodies, is associated with clinical activity.
Authors: Bing Li; Daniel J Allendorf; Richard Hansen; Jose Marroquin; Daniel E Cramer; Claire L Harris; Jun Yan Journal: Cancer Res Date: 2007-08-01 Impact factor: 12.701
Authors: Yi-Fan Hsu; Daniel Ajona; Leticia Corrales; Jose M Lopez-Picazo; Alfonso Gurpide; Luis M Montuenga; Ruben Pio Journal: Mol Cancer Date: 2010-06-07 Impact factor: 27.401
Authors: Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg Journal: N Engl J Med Date: 2008-10-23 Impact factor: 91.245
Authors: G Milano; M-C Etienne-Grimaldi; L Dahan; M Francoual; J-P Spano; D Benchimol; M Chazal; C Letoublon; T André; F-N Gilly; J-R Delpero; J-L Formento Journal: Ann Oncol Date: 2008-07-15 Impact factor: 32.976
Authors: Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang Journal: J Clin Oncol Date: 2008-03-03 Impact factor: 44.544
Authors: Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea Journal: Nat Rev Drug Discov Date: 2019-07 Impact factor: 84.694
Authors: Chuan Chen; Na Man; Fan Liu; Gloria Mas Martin; Hidehiro Itonaga; Jun Sun; Stephen D Nimer Journal: Cancer Res Date: 2022-06-06 Impact factor: 13.312
Authors: Claire Barton; Kim Vigor; Robert Scott; Paul Jones; Heike Lentfer; Heather J Bax; Debra H Josephs; Sophia N Karagiannis; James F Spicer Journal: Cancer Immunol Immunother Date: 2016-07-29 Impact factor: 6.968
Authors: Anissa S H Chan; Adria Bykowski Jonas; Xiaohong Qiu; Nadine R Ottoson; Richard M Walsh; Keith B Gorden; Ben Harrison; Peter J Maimonis; Steven M Leonardo; Kathleen E Ertelt; Michael E Danielson; Kyle S Michel; Mariana Nelson; Jeremy R Graff; Myra L Patchen; Nandita Bose Journal: PLoS One Date: 2016-11-03 Impact factor: 3.240